UK-based pharmaceutical company AstraZeneca has received more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) to develop, manufacture and deliver a Covid-19 vaccine developed by the University of Oxford.
Last month, AstraZeneca signed an agreement with the University of Oxford to develop and distribute the university’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company has now finalised its licence agreement for the recombinant adenovirus vaccine, renamed AZD1222. In addition, the company has committed to supporting the formation of a joint research centre at Oxford University focused on pandemic preparedness research.
